Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Eszopiclone First, Zopiclone Second, Placebo Third	3 mg eszopiclone during first intervention period, 7.5 mg zopiclone during second intervention period (after 4-14 day washout period), placebo during third intervention period (after 4-14 day washout period)
Eszopiclone First, Placebo Second, Zopiclone Third	3 mg eszopiclone during first intervention period, placebo during second intervention period (after 4-14 day washout period), 7.5 mg zopiclone during third intervention period (after 4-14 day washout period)
Zopiclone First, Eszopiclone Second, Placebo Third	7.5 mg zopiclone during first intervention period, 3 mg eszopiclone during second intervention period (after 4-14 day washout period), placebo during third intervention period (after 4-14 day washout period)
Zopiclone First, Placebo Second, Eszopiclone Third	7.5 mg zopiclone during first intervention period, placebo during second intervention period (after 4-14 day washout period), 3 mg eszopiclone during third intervention period (after 4-14 day washout period)
Placebo First, Eszopiclone Second, Zopiclone Third	Placebo during first intervention period, 3 mg eszopiclone during second intervention period (after 4-14 day washout period), 7.5 mg zopiclone during third intervention period (after 4-14 day washout period)
Placebo First, Zopiclone Second, Eszopiclone Third	Placebo during first intervention period, 7.5 mg zopiclone during second intervention period (after 4-14 day washout period), 3 mg eszopiclone during third intervention period (after 4-14 day washout period)

Participant Flow for 5 periods

Period 1:   First Intervention

	Eszopiclone First, Zopiclone Second, Placebo Third	Eszopiclone First, Placebo Second, Zopiclone Third	Zopiclone First, Eszopiclone Second, Placebo Third	Zopiclone First, Placebo Second, Eszopiclone Third	Placebo First, Eszopiclone Second, Zopiclone Third	Placebo First, Zopiclone Second, Eszopiclone Third
STARTED	16	15	15	15	15	15
COMPLETED	16	15	14	15	14	15
NOT COMPLETED	0	0	1	0	1	0
Withdrawal by Subject	0	0	1	0	0	0
Protocol Violation	0	0	0	0	1	0

Period 2:   First 4-14 Day Washout Period

	Eszopiclone First, Zopiclone Second, Placebo Third	Eszopiclone First, Placebo Second, Zopiclone Third	Zopiclone First, Eszopiclone Second, Placebo Third	Zopiclone First, Placebo Second, Eszopiclone Third	Placebo First, Eszopiclone Second, Zopiclone Third	Placebo First, Zopiclone Second, Eszopiclone Third
STARTED	16	15	14	15	14	15
COMPLETED	16	15	14	15	14	15
NOT COMPLETED	0	0	0	0	0	0

Period 3:   Second Intervention

	Eszopiclone First, Zopiclone Second, Placebo Third	Eszopiclone First, Placebo Second, Zopiclone Third	Zopiclone First, Eszopiclone Second, Placebo Third	Zopiclone First, Placebo Second, Eszopiclone Third	Placebo First, Eszopiclone Second, Zopiclone Third	Placebo First, Zopiclone Second, Eszopiclone Third
STARTED	16	15	14	15	14	15
COMPLETED	16	15	13	14	14	15
NOT COMPLETED	0	0	1	1	0	0
Adverse Event	0	0	1	0	0	0
Withdrawal by Subject	0	0	0	1	0	0

Period 4:   Second 4-14 Day Washout Period

	Eszopiclone First, Zopiclone Second, Placebo Third	Eszopiclone First, Placebo Second, Zopiclone Third	Zopiclone First, Eszopiclone Second, Placebo Third	Zopiclone First, Placebo Second, Eszopiclone Third	Placebo First, Eszopiclone Second, Zopiclone Third	Placebo First, Zopiclone Second, Eszopiclone Third
STARTED	16	15	13	14	14	15
COMPLETED	16	15	13	14	14	15
NOT COMPLETED	0	0	0	0	0	0

Period 5:   Third Intervention

	Eszopiclone First, Zopiclone Second, Placebo Third	Eszopiclone First, Placebo Second, Zopiclone Third	Zopiclone First, Eszopiclone Second, Placebo Third	Zopiclone First, Placebo Second, Eszopiclone Third	Placebo First, Eszopiclone Second, Zopiclone Third	Placebo First, Zopiclone Second, Eszopiclone Third
STARTED	16	15	13	14	14	15
COMPLETED	16	15	13	14	14	15
NOT COMPLETED	0	0	0	0	0	0

Reporting Groups

	Description
Entire Study Population	No text entered.

Baseline Measures

	Entire Study Population
Number of Participants   [units: participants]	91
Age   [units: years] Mean ± Standard Deviation	29.8  ± 3.87
Gender   [units: participants]
Female	46
Male	45
Race/Ethnicity, Customized   [units: participants]
White	63
African American/African Heritage	14
Asian-Central/South Asian Heritage	6
Asian-South East Asian Heritage	5
Asian-East Asian Heritage	3

1.  Primary:

Mean Tracking Error Assessed During the Continuous Tracking Test (CTT)   [ Time Frame: 7.5, 8, 8.5, 9, and 9.5 hours post-dose (double-blind) ]

2.  Secondary:

Mean Tracking Error (MTE) Assessed During the CTT   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

3.  Secondary:

CTT Mean Reaction Time   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

4.  Secondary:

Critical Flicker Fusion Test–Ascending Threshold   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

5.  Secondary:

Critical Flicker Fusion Test –Descending Threshold   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

6.  Secondary:

Critical Flicker Fusion Test–Overall Threshold   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

7.  Secondary:

Total Number of Attempted Symbol Substitutions, as Assessed by the Digit Symbol Substitution Test   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

8.  Secondary:

Total Number of Correct Symbol Substitutions, as Assessed by the Digital Symbol Substitution Test   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

9.  Secondary:

1-Back Percentage of Correct Responses   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

10.  Secondary:

3-Back Percentage of Correct Responses   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

11.  Secondary:

1-Back Reaction Time   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

12.  Secondary:

3-Back Reaction Time   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

13.  Secondary:

Sedation Score, as Assessed by the Linear Analogue Rating Scales   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

14.  Secondary:

Mood Score, as Assessed by the Linear Analogue Rating Scales   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]

15.  Secondary:

Coordination Score, as Assessed by the Linear Analogue Rating Scales   [ Time Frame: 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, and 11.5 hours post-dose (double-blind) ]